December 14, 2022 – Florence, Italy Baebies today announced it is expanding its partnership with medical device supplier Medical Horizons S.r.L to help bring newborn screening solutions to a greater …
Rich West Named Entrepreneur Of The Year® 2022 Southeast Award Finalist
Celebrating ambitious pioneers tackling our biggest challenges May 12, 2022 Ernst & Young LLP (EY US) has named our CEO, Richard West, as an Entrepreneur Of The Year® 2022 Southeast …
Baebies Earns CE Mark for FINDER SARS-CoV-2 Testing Platform
DURHAM, N.C. – (March 24, 2022) – Baebies® announced today it has received CE Mark for its FINDER® SARS-CoV-2 point-of-care test, which performs RT-PCR testing to detect SARS-CoV-2 on the …
Detection of Omicron Variant on FINDER SARS-CoV-2 Test*
November 29, 2021 Omicron1 is a new SARS-CoV-2 variant first reported in South Africa and Botswana. The World Health Organization (WHO) designated Omicron a Variant of Concern (VOC) due to its …
Baebies Awarded $3M Grant for Pediatric Coagulation Testing
Baebies was recently awarded a Phase IIB SBIR grant from the National Institutes of Health (NIH) for a project to develop a coagulation test panel utilizing very small volumes of blood with a rapid turn-around time.
Baebies Awarded Phase IIB SBIR Grant for Hyperbilirubinemia Testing Solution
Baebies was recently awarded a Phase IIB SBIR grant from the National Institutes of Health (NIH) for a project to focus on developing a more comprehensive screening method for hyperbilirubinemia (HBR) in newborns.
Baebies is Global
Expecting families in Qatar will soon have access to screen their babies for lysosomal storage disorders (LSDs) including Pompe disease, MPS I, Fabry and Gaucher. Qatar’s newborn screening lab is getting up and running with Baebies SEEKER, the first FDA-cleared and CE-marked newborn screening platform for LSDs.
Celebrating Shipment of 3,000,000th Test!
Baebies is celebrating the shipment of more than 3 million tests which translates to more than 3 million chances for a healthy start. We proudly share this milestone and our growth with babies everywhere.
Newborn Screening Legislation Expands Test Panels in Several US States
Missouri will be the first state in the US to screen for mucopolysaccharidosis II (MPS II), otherwise known as Hunter syndrome and spinal muscular atrophy (SMA), two life threatening genetic diseases. The state is already screening for several LSDs using the SEEKER platform. Florida recently passed legislation that requires the Advisory Council to consider every condition added to the RUSP within 1 year, and if recommended, the NBS lab would be required to screen for that condition within 18 months.
Baebies Advisor Priya Kishnani Named 2016 Rare Disease Hero in Lysosomal Storage Disorders
Baebies congratulates Duke’s Priya Kishnani, MD, PhD, who currently serves on the company’s Advisory Board, on being named one of the 2016 Rare Disease Heroes. The first annual Rare Disease Hero Recognition Gala, held on October 17 honors five healthcare institutions and their medical teams for outstanding contributions in the rare disease community.
- Page 1 of 2